Back to Search
Start Over
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
- Source :
-
Oncology [Oncology] 2016; Vol. 90 (2), pp. 69-78. Date of Electronic Publication: 2016 Jan 16. - Publication Year :
- 2016
-
Abstract
- Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC).<br />Methods: Thirty patients with progressing CRPC and a rising prostate-specific antigen (PSA) received docetaxel/prednisone in standard conditions for 6 cycles in combination with per os curcumin, 6,000 mg/day (day -4 to day +2 of docetaxel). The co-primary endpoint was the overall response rate determined by PSA and target assessments. An ancillary study assessed the seric values of chromogranin A (CgA) and neuron-specific enolase (NSE).<br />Results: Twenty-six patients received the scheduled treatment, 2 progressed and 2 died before the end of treatment. A PSA response was observed in 59% of patients (14% of PSA normalization) and achieved within the first three cycles for 88% of responders. Partial response was reached for 40% of evaluable patients. The regimen was well tolerated, and no adverse event was attributed to curcumin. Twenty patients were 100% curcumin compliant. The PSA level and objective response rate were not correlated with the serum values of CgA and NSE.<br />Conclusion: This study produced additional data on curcumin as a treatment for cancer, with a high response rate, good tolerability and patient acceptability, justifying the interest to conduct a randomized trial.<br /> (© 2016 S. Karger AG, Basel.)
- Subjects :
- Adenocarcinoma secondary
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols adverse effects
Chromogranin A blood
Curcumin administration & dosage
Curcumin adverse effects
Docetaxel
Geriatric Assessment
Humans
Male
Medication Adherence
Middle Aged
Phosphopyruvate Hydratase blood
Pilot Projects
Prednisone administration & dosage
Prostate-Specific Antigen blood
Prostatic Neoplasms, Castration-Resistant blood
Prostatic Neoplasms, Castration-Resistant pathology
Survival Rate
Taxoids administration & dosage
Treatment Outcome
Adenocarcinoma drug therapy
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Prostatic Neoplasms, Castration-Resistant drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1423-0232
- Volume :
- 90
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 26771576
- Full Text :
- https://doi.org/10.1159/000441148